News
bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has entered into an agreement to acquire SpinChip Diagnostics ASA (“SpinChip”), a privately held Norwegian diagnostics company that has developed a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted to near patient testing as it can deliver a result from a whole blood sample within 10 minutes with the same high-sensitivity performance as the laboratory instruments.
Swipe to discover more
-
bioMérieux to present at the 43rd Annual J.P. Morgan HealthCare Conference
Marcy l’Étoile, France, January 13, 2025 – bioMérieux, a world leader in the field in vitro diagnostics, today announces its participation in the 43rd Annual J.P. Morgan Healthcare Conference, to be held in San Francisco, USA, from January 13 to 16, 2025. -
What’s next in food safety? Key trends for 2025 and beyond
At bioMérieux, we proudly operate at the forefront of diagnostics, supporting customers across the food and drinks industry to help protect consumers and strive for the very highest standards of safety and quality. As we enter 2025, we reflect on the trends we can expect to see in this important sector this year. -
With E-Resale, bioMérieux innovates by giving a second life to its instruments
Launched last July, starting with Africa and Middle East, the E-Resale platform allows to purchase and sell second-hand bioMérieux instruments for clinical applications. This is an innovative offer in the field of circular economy and a first on the in vitro diagnostics market.
Enabling Decision-Making
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19